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Disease heterogeneity is as major issue in Type II Diabetes Mellitus (T2DM), and this patient inter-variability might
not be sufficiently reflected by measurements of glycated haemoglobin (HbA1c).
Β-cell dysfunction and β-cell death are initiating factors in development of T2DM. In fact, β-cells are known vanish
prior to the development of T2DM, and autopsy of overt T2DM patients have shown a 60% reduction in
β-cell mass.
As the decline in β-cell function and mass have been proven to be pathological traits in T2DM, methods for
evaluating β-cell loss is becoming of more interest. However, evaluation of β-cell death or loss is currently invasive
and unattainable for the vast majority of diabetes patients. Serological markers, reflecting β-cell loss would be
advantageous to detect and monitor progression of T2DM. Biomarkers with such capacities could be neo-epitopes
of proteins with high β-cell specificity containing post translational modifications. Such tools may segregate T2DM
patients into more appropriate treatment groups, based on their β-cell status, which is currently not possible.
Presently individuals presenting with adequately elevated levels of both insulin and glucose are classified as T2DM
patients, while an important subdivision of those is pending, namely those patients with sufficient β-cell capacity
and those without. This may warrant two very different treatment options and patient care paths.
Serological biomarkers reflecting β-cell health status may also assist development of new drugs for T2DM and aid
physicians in better characterization of individual patients and tailor individual treatments and patient
care protocols.
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Personalized treatmentIntroduction
Type II Diabetes Mellitus (T2DM) is a heterogeneous
type of disease [1], meaning that affected patients display
a large variability with regards to disease characteristics.
This patient heterogeneity is not sufficiently illustrated
by the currently available and gold standard biomarkers
for evaluation of T2DM: Fasting plasma glucose (FPG),
oral glucose tolerance test (OGTT) and glycated haemo-
globin A1c (HbA1c). These markers efficiently reflect* Correspondence: mk@nordicbioscience.com
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distribution, and reproduction in any mediumblood glucose status, but they cannot characterize
T2DM patients at a more detailed level, for example
with regards to pancreatic function, peripheral effects of
insulin and progression of secondary complications of
the disease.
Hence novel biomarkers with the potential to segre-
gate different T2DM patient subtypes will be imperative
to deliver the best possible treatment to the individual
patient in the future. A new panel of diabetes biomar-
kers is needed to identify and characterize these future
patient subtypes and assign appropriate subtype treat-
ments. Also drug development of novel T2DM treat-
ments would benefit from biomarkers contributing with
more elaborate pathological information.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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those reflecting the health or death of β-cells [2]. β-cells
are the focal point in both Type I Diabetes Mellitus
(T1DM) and T2DM, because of their capacity to pro-
duce and secrete insulin. In both types of diabetes, β-
cells are lost [3,4]. The vast majority of T1DM patients
display a dramatic loss of β-cells as a consequence of a
cell-mediated autoimmune attack on the β-cells, with
consequent insulin deficiency and chronic hypergly-
caemia [3]. At time of diagnosis, T1DM patients have
had their β-cell mass reduced by 70-80% [5]. Patients
suffering from T1DM are often lean and display a
healthy phenotype when their insulin deficiency is prop-
erly treated. This is in contrast to T2DM patients, who
often are overweight or obese and display a metabolic
phenotype, which complicates the overall pathology.
Loss of β-cells is an initiating event in development of
T2DM and may occur gradually and long before the dis-
ease is diagnosed [4]. A 40% reduction in β-cell mass
has been observed in obese individuals with impaired
fasting glucose (IFG), and a 60% reduction has been
observed in patients suffering from overt T2DM [4,6].
Furthermore, a strong correlation between decline in β-
cell area and development of T2DM has been estab-
lished in patients suffering from pancreatic disorders [7].
These findings clearly indicate that when the β-cell mass
declines considerably, the body can no longer uphold
normal glucose regulation, with development of T2DM
as consequence.
It is often not well established how current and novel
drugs for management of T2DM affect the β-cells at a
more detailed level, despite the apparent need for im-
proving this aspect of the disease. Biomarkers reflecting
β-cell death and β-cell mass could aid in evaluation of
positive and/or negative effects on β-cells inflicted by
different types of drugs, and novel β-cell biomarkers
could therefore be advantageous in future drug develop-
ment programs.
The ability to detect β-cell loss could facilitate progno-
sis of disease development of T2DM at a much earlier
point in time than any of the currently used diabetes
biomarkers such as FPG, OGTT and HbA1c. In addition,
different sub-groups of T2DM patients are highly likely
to lose β-cells at different rates, and these differences
may require different treatment regimens for individual
patients [7]. Serological biomarkers reflecting β-cell
death and β-cell volume would therefore be valuable
tools for disease prognosis, early diagnosis and tailoring
treatment to the individual.
Today, evaluations of β-cell mass are only rarely per-
formed, as this currently requires obtaining biopsies,
which is an invasive procedure to the patient. Post-
mortem histological evaluations of β-cell mass can be
performed, but these examinations will not elucidatedecline in β-cell mass during disease. Furthermore,
histological assessment of β-cell death is complicated by
the fact that dead cells are rapidly removed from the is-
lets by macrophages [4]. Serological biomarkers reflect-
ing β-cell mass or β-cell death have the strong advantage
of being non-invasive, and such markers could, like
HbA1c, be used as continuous evaluation of disease de-
velopment and disease management.
Potential serological biomarkers reflecting β-loss could
be specific neo-epitopes of β-cell related proteins. When
β-cells are being lost by apoptosis or necrosis [5], site-
specific cleavage of β-cell specific proteins is expected to
arise from cleavage by particular proteases, creating neo-
epitopes for measurement in serum. By this mechanism
a particular protein fingerprint is generated, and investi-
gations of this specific protein fingerprint could provide
information about pathological processes [8]. Measure-
ments of neo-epitopes have in several diseases been
shown to correlate with disease pathology [9-15], as
generation of specific neo-epitopes arise from specific
pathological processes [8,16,17]. An incomplete list of
β-cell proteins that might be of interest as novel bio-
markers could include insulin, amylin, incretin recep-
tors, special neuronal proteins and proteins which act as
autoantigens in T1DM.
In the current review we describe how new biomarkers
reflecting β-cell loss are desired to better identify people
at risk of developing T2DM, to diagnose the disease
earlier than is possible with current biomarkers, to better
characterize affected patients, to optimize individual
treatment, and to evaluate the effects of drugs on β-cells.
We will in this paper describe the pursuit of novel β-cell
neo-epitope biomarkers that could improve the clinical
diagnosis and management of diabetes.
Overview of T2DM
T2DM is a major cause of morbidity and mortality in
the industrialized world, and cardiovascular complica-
tions affect as many as 50% of all T2DM patients [18].
The global prevalence of T2DM is rapidly increasing,
and the number of people diagnosed with the disease
worldwide has more than doubled over the past three
decades, primarily due to a dramatic increase in number
of obese people, as obesity is a major risk factor for de-
velopment of T2DM [19]. Previously T2DM was consid-
ered a disease of the elderly, however, with increasing
numbers of obese individuals of all ages, including chil-
dren and adolescents, T2DM is now observed at all ages
[19]. It is estimated that the prevalence of both type I
and type II diabetes was 285 million in 2010, and this
number is expected to increase to around 440 million by
2030, which represents 7.7% of the total adult population
of the world aged 20–79 years [19]. Of the total popula-
tion of diagnosed diabetics, at least 90% suffer from
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40-50% of people affected by T2DM or the stages pre-
ceding overt T2DM are undiagnosed [20].
β-cell physiology and T2DM pathology
The human pancreas acts as both an exocrine and endo-
crine gland to aid the digestive system. The exocrine se-
cretion of pancreatic juice into the duodenum aid the
digestion of consumed nutrients. The pancreas also con-
sists of highly vascularized and innervated endocrine
mini-organs, called the islets of Langerhans, which make
up 1-2% of the pancreatic mass, and which secrete
several important hormones into the circulation. Each
pancreatic islet includes at least five types of hormone-
secreting cells (α-cells; β-cells; δ-cells; PP cells and ε-cells),
of which the β-cell and α-cell secretes insulin and gluca-
gon, respectively, and these pancreatic hormones are the
dominant hormonal regulators of glucose metabolism. For
a thorough review of pancreatic endocrine function we
refer to the following reviews [21,22].
The β-cells constitute about 70-80% of pancreatic islet
cells [23] and upon β-cell exposure to various stimuli in-
cluding: [glucose, amino acids, free fatty acids, gastro-
intestinal hormones and neural stimuli], stored
pro-insulin in granules is rapidly cleaved into insulin
and C-peptide, which are released into the circulation.
Amylin, which is also stored in the insulin storage gra-
nules, are co-secreted together with insulin, and accu-
mulation of this protein in and around β-cells in states
of insulin hypersecretion, may contribute to islet path-
ology as describe in the following section. A primary
stimulus for insulin secretion is elevation of blood glu-
cose above the fasting level, which is normally between
4.5-5.5mM. Insulin is an essential anabolic hormone that
promotes sequestration of carbohydrate, fat and protein
in storage depots throughout the body by exerting
powerful actions principally on skeletal muscle, liver and
adipose tissue. Insulin inadequacy, due to insufficient in-
sulin production, as occur in T1DM, is characterized by
lifelong dependency of exogenous insulin administration
[24], as absence of insulin is correlated with impeded
human survival.
T2DM is a complex metabolic disease, characterized
by elevated plasma glucose levels, loss of β-cell function
and insulin resistance leading to disruption of the carbo-
hydrate/lipid metabolism [25]. Decreased β-cell function
and decreased insulin sensitivity in muscle, liver, pan-
creas and adipose tissue, result in elevated basal plasma
glucose concentrations and/or impaired plasma glucose
clearance after meal consumption [26]. The elevated
plasma glucose is the cause of most clinical symptoms
associated with T2DM such as compromised micro-
vasculature, β-cell destruction, liver lesions, muscle atro-
phy, neuropathy, nephropathy, cross-linking of proteinsby advanced glycation end-products (AGEs) causing fra-
gile bones, and the most severe complication – accelerated
artherosclerosis with increased risk of heart failure and
stroke [26-28] (illustrated in Figure 1).
Before the onset of actual T2DM, patients can be diag-
nosed with impaired glucose tolerance or prediabetes,
which are two pathological terms with great diagnostic
overlap [19,29]. The diagnosis of T2DM has been
recommended by both World Health Organization
(WHO) and American Diabetes Association (ADA) to
be established if HbA1c concentrations in blood are
6.5% (48mmol/mol) or higher [19]. For an introduction
to HbA1c we recommend a review by Krishnamurti
et al. [30].
An illustration of development of blood glucose, fast-
ing serum insulin and insulin resistance during initiation
and progression of T2DM is depicted in Figure 2A.
Blood glucose gradually increases during initiation and
progression of the disease, whereas insulin resistance
primarily is increased before the diagnosis of T2DM
[31]. Fasting serum insulin is actually increased in a
period leading up to the diagnosis of T2DM, after which
it will decline due to β-cell dysfunction and decreased β-
cell mass [31]. It should be noted, however, that high
fasting insulin levels (hyperinsulinemia) often occur at
the same time as reduced insulin secretion upon glucose
stimulation, due to β-cell dysfunction [32]. Furthermore,
these two phenomena - elevated fasting insulin and
reduced acute insulin secretion - are independent pre-
dictors of progression from normal to impaired glucose
tolerance [32], which is a known risk factor for develop-
ment of T2DM. The hyperinsulinemic state indicates
that the β-cells are in constant overdrive, which leads to
exhaustion of the β-cells, according to the overworked
β-cell hypothesis [32,33]. It has been suggested that re-
lieving the β-cells in the pre-diabetes state by inhibition
of insulin secretion, would be a sensible way to protect
the β-cells and thus lower the risk of development of
diabetes [32].
In healthy individuals, insulin sensitivity and β-cell se-
cretion of insulin are inversely and proportionally corre-
lated. The product of these two parameters is constant
and referred to as the disposition index [35]. For indivi-
duals developing T2DM this correlation is gradually
lost, as the β-cells cannot meet the demand for excess
insulin when insulin sensitivity is decreasing [4], as illu-
strated in Figure 2B. The relative contributions, to the
progression of T2DM, of impaired insulin sensitivity
and decreased β-cell function is controversial [1,4].
However, it appears that impaired β-cell function is a
stronger predictor of development of T2DM than insu-
lin resistance [1,4]. Being able to measure β-cell loss
would be useful to assess the prognosis of T2DM in in-
dividual patients.
Figure 1 Complications in T2DM related to increased blood glucose. Elevated blood glucose can lead to the illustrated pathologies:
destruction of β-cells, hepatobiliary lesions, muscle atrophy, neuropathy, nephropathy, formation of peripheral advanced glycation end-products
(AGEs), accelerated atherosclerosis and damaged vasculature.
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more of the pathological changes involved in T2DM,
such as reducing the surplus blood glucose; normalizing
islet function; improving fat tissue functionality and
distribution; weight loss; and enhancing energy expend-
iture. Currently available treatments for T2DM include
metformin, sulphonylureas, meglitinides, glitazones,
glucagon-like peptide-1(GLP-1) analogues, dipeptidyl
peptidase-4 (DPP-4) inhibitors, and insulin supplemen-
tation. While these in most cases are efficient in redu-
cing fasting blood glucose and HbA1c levels, they are
limited by a range of factors, such as loss of efficacy over
time, intolerance, the need for injection, lack of effects
on β-cells, and side effects including weight gain,
hypoglycemia, fluid retention, heart failure, bone loss
and others [19,36]. Thus, there is a continued search
and need for novel treatments of T2DM. With novel
tools to directly monitor β-cell function and life-span,
new compounds which protect β-cell populations could
be identified.
The vulnerable β-cell
In several studies it has been shown that development of
T2DM and progression is associated with loss of func-
tion of β-cells and a loss of β-cell mass [4,6,7,37]. Obese
subjects with impaired fasting glucose (IFG), who are at
increased risk of developing T2DM, display a 40% reduc-
tion in β-cell volume compared with non-diabetic obesecontrols [6]. Furthermore, it has been established that
islet function is about 50% of normal at the time of
T2DM diagnosis [34], and a reduction of 60% in β-cell
volume has been established at necropsy of obese
patients suffering from overt T2DM [4,6]. In addition,
manifestation of pancreatic diabetes, in patients with
underlying pancreatic disorders, appears when β-cell
area has declined with approximately 65% [7]. The
decline in β-cell mass was found to relate to increased
β-cell apoptosis, whereas islet formation and β-cell repli-
cation remains normal in T2DM patients [4,6].
Figure 2C shows the decline in β-cell volume as reported
in the literature. It should be mentioned, however, that a
separate study identified a reduction in β-cell volume of
only 24% in subjects with 1–5 years of overt diabetes
[37]. Regardless of the precise reduction in β-cell volume
and mass, several lines of evidence suggest that β-cell
mass is progressively lost during initiation and progres-
sion of T2DM [4,6,7,37], and the development of T2DM
is likely to be a combination of β-cell loss and β-cell
functional deficiency [4,19,37].
Several pathological processes lead to β-cell dysfunc-
tion and death, as illustrated in Figure 3. These include
glucotoxicity, lipotoxicity, inflammation and amyloid de-
position, which will be described briefly below. For a
more elaborate review of these processes, we refer to
Wajchenberg [4]. When β-cells undergo death or be-
come dysfunctional, an array of proteins is expected to
Figure 2 Characteristics of T2DM development and progression. A) Overview of changes in blood glucose, fasting serum insulin and insulin
resistance during the initiation and progression of T2DM. Modified from [31]. B) Disposition index indicating the relationship between insulin
sensitivity and insulin secretion in β-cells of normal individuals and T2DM patients. C) Β-cell loss during disease progression in T2DM. The graph is
based on findings by Butler et al. and Holman et al. [6,34]. (IFG = Impaired fasting glucose).
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and released to circulation, as shown in Figure 3. Identi-
fying such disease specific PTMs in circulation, could
provide direct evidence of β-cell loss.
Glucotoxicity
Glucotoxicity is caused by prolonged exposure to supra-
physiological concentrations of glucose, resulting in β-
cell damage that may become irreversible [38,39]. Even
transient exposure to supraphysiological glucose concen-
trations, as occurs in the pre-diabetes stage, might also
have detrimental effects on β-cells [4,38], and could par-
tially explain the observed decrease in β-cell mass before
onset of T2DM.
Β-cells are by nature extremely sensitive to changes
in glucose concentrations, and for this reason, pro-
longed exposure to high glucose concentrations is a
major stress factor for these cells specifically. A high
glucose concentration is a signal for high insulin pro-
duction, which over time will impose a significant load
on the endoplasmic reticulum (ER), eventually leading
to ER stress (Figure 3), which has been shown to in-
duce pro-apoptotic signals [4,40]. In addition to ERstress, high levels of glucose are known to induce oxi-
dative stress by generation of reactive oxygen species
(ROS) [38,39], as illustrated in Figure 3. ROS are
highly damaging to β-cells, leading to β-cell dysfunc-
tion and even cell death [38,39]. Islet cells are in
particular very vulnerable to ROS, as only low levels
of antioxidant enzymes are expressed in the pancreatic
islets [4,38,39].
Lipotoxicity
Experiments have shown that exposure of β-cells to high
concentrations of free fatty acids (FFA) is not toxic
to the cells when administered in combination with
physiological glucose levels. However, high concentra-
tions of FFA have been observed to have toxic effects on
β-cells when glucose levels are elevated, indicating that
lipotoxicity only occurs during hyperglycemia [4,39,41]
(Figure 3).
In addition, lipoproteins have been shown to affect β-
cells. Very low-density and low-density lipoproteins have
been demonstrated to exert pro-apoptotic effects on β-
cells, whereas high-density lipoproteins have been shown
to protect against pro-apoptotic effects [42]. These
Figure 3 Pathological processes leading to β-cell failure and death. Several pathological processes can contribute to β-cell failure and β-cell
death. These includes: Glucotoxicity, lipotoxicity, accumulation of islet amyloid polypeptide and inflammation. When β-cells become dysfunctional
or undergo death, some β-cell proteins will undergo modifications by post translational modifications, and be released to circulation.
(ER = endoplasmatic reticulum, IAPP = islet amyloid polypeptide, ROS = reactive oxygen species, PTMs = post translational modifications).
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contribute to disease pathogenesis and progression of β-
cell failure [4,42].
Inflammation
Increased inflammatory mediators are common in
T2DM (Figure 3). The inflammatory mediators are
known to affect blood vessels and insulin-sensitive tis-
sues, but evidence also suggests that inflammatory cyto-
kines affect the β-cells directly by impairing their
secretory function or inducing apoptosis [4]. An example
is leptin, a pro-inflammatory cytokine produced by adi-
pocytes, which has been shown to induce apoptosis in
human β-cells after chronic exposure [4].
Β-cell apoptosis itself, induced by some of the several
processes described here, is also indicated as a process
that can provoke an auto-immune response, directed
against the β-cells, as seen in “classical” T1DM [4].
Amyloid depositions
Depositions of amylin or islet amyloid polypeptide
(IAPP) have been reported in up to 90% of T2DM
patients, and it has for long been debated whether these
depositions contribute to deterioration of β-cell function
and ultimately β-cell death [4] (Figure 3). Depositions of
IAPP around the β-cells occur as a consequence ofuncorrected protein misfolding, caused by ER stress
within the β-cells [43]. Soluble IAPP oligomers have
been shown to exert toxic effects on β-cells and induce
apoptosis, whereas stabilized IAPP depositions appear
inert and non-toxic to the cells [6,44-47].
In states of insulin hyper-secretion, taking place prior
to T2DM development (Figure 2A), high levels of amylin
will also be secreted from the β-cells, which can con-
tribute to amyloid deposition and thereby contribute to
islet pathology in T2DM [6,43-47].
In summary, β-cells are vulnerable cells. Several
pathological processes, as described above, progres-
sively lead to decreased β-cell function, which mani-
fests as decreased insulin synthesis and secretion, and
can lead to β-cell failure and ultimately cell death
[38,39], as illustrated in Figure 3. As β-cell dysfunction
and death are some of the early initiating events,
which over time can progress into development of
T2DM, it would be valuable, with a simple and con-
venient test, to continuously assess β-cell functionality
and β-cell death to better identify persons at risk of
developing T2DM [2]. It should be possible to identify
specific biomarkers which reflect the described changes
inflicted on the β-cells, as β-cell failure and β-cell
death will leave serological traits (Figure 3), which are
currently unidentified.
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The application of serological biomarkers in the clinic
requires a high level of clinical validation and quantifica-
tion. The BIPED (Burden of disease, Investigative,
Prognostic, Efficacy of intervention and Diagnostic) classi-
fication of biomarkers was originally defined by the Osteo-
arthritis Biomarkers Network, a National Institutes of
Health (NIH)-funded multidisciplinary group, but has
since been adapted for other diseases, such as liver fibrosis
[48,49]. The Burden of disease markers assesses the se-
verity or extent of disease, typically at a single point in
time, among individuals with a given disease (e.g. dia-
betes). The Investigative marker lacks sufficient informa-
tion to allow for its inclusion in one of the other
biomarker categories. The investigative category includes
markers for which a relationship to various normal and
abnormal biological processes has been identified, how-
ever has not yet been confirmed in human subjects. The
key feature of a Prognostic marker is the ability to pre-
dict the future onset of disease among individuals with-
out established disease or the progression of disease
among those with the disease. Another application of
prognostic markers is for prediction of response to
treatment. An Efficacy-of-intervention biomarker pro-
vides information about the efficacy of treatment among
persons with the disease. Diagnostic markers are
defined by the ability to classify individuals as either
having or not having a disease [48].
Another aspect of biomarker development is the
awareness of their application. The US Food and Drug
Administration (FDA) critical path initiative was
launched in 2004 [50,51], with an overall objective of
raising awareness about the cost of drug development
and the relatively small number of drugs reaching FDA
approval. Secondly, the critical path focused on the need
for developing biomarkers, which could substantially
shorten the time before important decisions were
needed during drug development, such as ascertaining
whether a drug’s effects would likely translate from ani-
mal to man, a rapid go-no-go decision following a phase
I clinical study, narrowing of the dose-range from a
phase II study, or predicting the right cohort before
entering a phase III trial [16,51].
Current markers in T2DM
As discussed earlier in this review, various tests are
already used to diagnose and characterize T2DM. As
defined in 2001 by the ‘Biomarkers Definitions Working
Group’ [52] most of these tools can be characterized as
biomarkers. Some have been in use for a long time,
whereas others are recent discoveries and others are still
subject to investigation. Current markers are described
below, and summarized in Table 1, with indication of
BIPED categories. The currently utilized biomarkers fallinto the following BIPED categories: Burden of disease
(B), Efficacy of intervention (E) and Diagnostic (D).
Glucose related biomarkers – FPG, OGTT and HbA1c
For decades, the gold standards for diagnosing diabetes
were based on blood glucose levels, either FPG or the two-
hour value in a standard OGTT [60]. Patients with a FPG
≥ 7.0 mmol/L or a 2h OGTT test value ≥ 11.1 mmol are
considered diabetic. HbA1c is an alternative way of meas-
uring the glucose level in circulation. HbA1c is a glycated
version of hemoglobin located in the red blood cells.
During the life-cycle of hemoglobin, which is approxi-
mately 3 months, a certain portion of the overall
hemoglobin will be glycated, depending on the glucose
level in blood. The HbA1c level is therefore proportional
to average blood glucose concentration over the previous
three months. In 2009, OGTT and FPG were replaced by
HbA1c as the gold standard for disease diagnosis, with a
T2DM diagnosis given at HbA1c concentrations of ≥ 6.5%
[29] (equivalent to 48mmol/mol [61]). However, the ADA
still recommends using a combination of HbA1c, FPG and
OGTT for monitoring T2DM or T2DM risk assessment.
β-cell derived biomarkers – Pro-insulin, insulin
and c-peptide
In healthy individuals, pro-insulin is initially stored in
immature secretory vesicles in the β-cells, which bud off
from the ER, and the protein is subsequently cleaved
into insulin and c-peptide by endo-peptidases in the
vesicle maturation process [62]. Pro-insulin secretion is
low under normal conditions, but is found to be elevated
in T2DM because it is not properly cleaved, either due
to increased β-cell stress [63] or due to dysfunction in
the secretory pathway of insulin [64]. The pro-insulin
level is used as a marker of insulin resistance [65] and is
often used in a pro-insulin/insulin ratio as an indicator
of β-cell dysfunction [65,66].
Fasting insulin can be measured to assess basal β-cell
productivity. In addition, insulin can be measured during
OGTT to assess insulin response to glucose load. C-
peptide is co-secreted with insulin in equivalent molar
concentrations, but has a significantly longer half-life in
the body than insulin; 20–30 min versus 3–5 min for in-
sulin [67]. Due to a longer half-life combined with low
hepatic retention, c-peptide is considered a more accurate
measurement of endogenous insulin secretion than insulin
itself [68].
Pro-insulin and c-peptide concentrations as well as
pro-insulin/insulin ratios are currently being utilized in
different Homeostasis Model Assessment (HOMA) mo-
dels to estimate β-cell function/dysfunction (HOMA-B)
and insulin sensitivity (HOMA-IS) [69]. Intact pro-insulin
and pro-insulin/(insulin/c-peptide) ratio assessments are
arguably the best current marker to assess β-cell stress/
Table 1 Biomarkers used in relation to T2DM
Biomarker Target Change in
T2DM
Advantages Disadvantages Examples of BIPED*
classification
HbA1C Blood
glucose
Elevated Easy and fast to measure. B, D:
No restrictions prior to
measurement.
Used as the Gold
standard for diagnosis
and monitoring of T2DM
[29]
E: HbA1C↓
Sulphonylureas+
Rosaglitazone [53]
Prioglitazone [54]
Balaglitazone and
Pioglitazone[55]
Liraglutide and Sitagliptin
[56]
DDP-IV inhibitor LC
15–0444 [57]
Fasting plasma
glucose (FPG)
Blood
glucose
Elevated Easy and fast to measure. Require patients to be
fasting prior to sampling
B, D:
Used in the diagnosis
and monitoring of T2DM
[29]
E: FPG ↓
Sulphonylureas+
Rosaglitazone [53]
Prioglitazone [54]
Balaglitazone and
Pioglitazone [55]
Liraglutide and
Sitagliptin [56]
DDP-IV inhibitor LC
15–0444 [57]
Oral glucose
tolerance test
(OGTT) or
Post-prandial
glucose
Blood
glucose
clearance
Glucose
clearance:
Impaired
OGTT: Accurate assessment of
functional glucose clearance by
liver or peripheral tissues
Two hour test. B, D:
Used in the diagnosis
and monitoring of T2DM
[29]
Post prandial
glucose:
Elevated
Post-prandial glucose: A less time-
consuming method to assess
glucose clearance than OGTT
Time consuming test
for the patient.
E: Improved OGTT
Prioglitazone [54]
E: Post prandial glucose ↓
Balaglitazone and
Pioglitazone [55]
Pro-insulin Β-cell
stress/
dysfunction
Elevated Only current marker to assess
β-cell dysfunction
Usually combined with
additional tests: Fasting
insulin, C-peptide
E: pro-insulin ↓
Split pro-insulin Proinsulin not directly influenced
by therapeutic injections of insulin
Exenatide [58]
Pro-insulin/
Insulin ratio
E: Split pro-insulin ↓
Prioglitazone [54]
E: Split pro-insulin→
Gliclazide [54]
E: pro-insulin/insulin ratio ↓
Liraglutide and
Sitagliptin [56]
Exenatide [58]
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Table 1 Biomarkers used in relation to T2DM (Continued)
Fasting Insulin Β-cell
functionality
Elevated in early
stages of disease
development.
Short half life of insulin Fasting insulin levels
changes with the
stages of pathogenesis
of T2DM
E: Fasting Insulin ↑
Decreased in late
stages of T2DM
Injections with insulin is
used as treatment in
T2DM
Gliclazide [54]
Chlorpropamide [59]
Glibenclamide[59]
Insulin[59]
E: Fasting Insulin →
Exenatide [58]
Liraglutide and
Sitagliptin [56]
E: Fasting Insulin ↓
Sulphonylureas+
Rosaglitazone [53]
Prioglitazone [54]
Metformin[59]
C-peptide Total insulin
secretion
Elevated in early
stages of disease
development.
Half life: C-peptide E: C-peptide ↓
Decreased in late
stages of T2DM
> Insulin. Improved assessment
of total insulin secretion
Sulphonylureas+
Rosaglitazone [53]
C-peptide not directly influenced
by therapeutic injections of insulin
Prioglitazone [54]
DDP-IV inhibitor LC
15–0444 [57]
E: C-peptide ↑
Liraglutide and
Sitagliptin [56]
Gliclazide [54]
*BIPED (Burden of disease, Investigative, Prognostic, Efficacy of intervention, Diagnostic).
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resistance and the progression of T2DM [70,71] and have
also been demonstrated to have some predictive power to
assess T2DM converters in the IRAS study [72,73]. How-
ever, its use to assess β-cell destruction/loss is only in-
direct and only useful in late stage T2DM as the β-cells
by then have lost most of the redundancy found in the in-
sulin secretory system. Novel biomarkers are needed that
can be directly linked to β-cell loss before the secretory re-
dundancy is lost and a biomarker that can directly deter-
mine whether the current level of β-cell stress/dysfunction
causes the β-cell population to decline or not.
Additional T2DM related biomarkers
One approach to establishing prognostic biomarkers for
T2DM is by combining of a broad spectrum of different
known markers to form a prognostic algorithm for
T2DM. This approach has been tested in several studies
[74-76]. In addition, Wang et al. found that a panel of
five amino acids have prognostic value in T2DM based
on investigation of metabolite profiles in individuals
who developed T2DM [77]. Adipokines are also an
interesting class of molecules with potential to becomebiomarkers due to the intricate relationship between
obesity and T2DM. Two recently discovered adipokines,
chemerin and omentin-1, have been shown to be ele-
vated or lowered in T2DM patients respectively [78],
making these two adipokines potential new T2DM bio-
markers. However, none of the biomarkers mentioned
here have been fully validated and none is currently used
for the general assessment of T2DM. These biomarkers
can therefore at best only be characterized as Investiga-
tive (I) under the BIPED classification.
Despite the existing biomarkers, there is still a general
lack of validated Prognostic (P) biomarkers for T2DM.
Biomarkers reflecting β-cell loss could become valuable
prognostic markers. In addition, such markers could also
prove to be efficient markers for assessment of Efficacy
of intervention (E), where the desired drug mode-of-
action (MOA) is on the β-cells.
Prior success with disease-specific post
translational modifications
Neo-epitopes are post-translational modifications (PTMs)
of proteins formed by processes such as protease cleavage,
citrullination, nitrosylation, glycosylation, isomerisation
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molecule that can be selected as a biochemical marker.
Each protein modification results from a specific local
physiological or pathological process [17]. Identifying neo-
epitopes which are related to specific diseases can be
visualized as finding specific protein fingerprints which re-
late to specific pathological changes.
The most commonly used neo-epitope biomarker in
the field of diabetes is HbA1c, and as described in this
paper, it is useful for monitoring response to treatment,
as well as supporting the diagnosis of diabetes. However,
changes in HbA1c levels occur slowly, and the magni-
tude of the changes is fairly small.
Another neo-epitope biomarker which has been used
extensively is the bone resorption marker β-CTX-I. The
use of this marker in the bone field has illustrated many
of the benefits and a few of the challenges of this class
of biomarkers [11].
In bone, the extracellular matrix (ECM) consists of 90%
type I collagen, and this matrix is degraded by the bone-
resorbing osteoclast [79-81]. The osteoclasts degrade type
I collagen using the cysteine proteinase cathepsin K, and
this has been shown to lead to the generation of the CTX-
I fragment (1207EKAHDGGR1214) [79,82-84], as illustrated
in Figure 4A. The CTX-I fragment hence contains a
cathepsin K cleavage site as its primary neo-epitope
(Figure 4A and D). However, in addition, it is a dipeptide
linked together via a lysine crosslink adding another neo-
epitope to the fragment [17,79], as seen in Figure 4B and
D. Finally, it contains a DG amino acid sequence, and,Figure 4 Formation and measurement of β-CTX-I neo-epitopes. A) En
cleavage specific noe-epitope. B) Enzymatic cross-linking of two type I coll
neo-epitope. C) Isomerization of aspatic acid (Asp) from α to β conformatio
neo-epitope of β-CTX-I containing specific cleaveage, cross-linking and isom
measurement of β-CTX-I.with time, this site undergoes isomerisation with a con-
formational change of aspartic acid from α conformation
to β conformation [17,79], as illustrated in Figure 4C. The
β-CTX-I system measures the isomerized, hence aged
form, whereas α-CTX-I measures the un-isomerized iso-
form. The isomerisation site thereby adds a third neo-
epitope to this specific CTX fragment [17,79] (Figure 4C
and D). Antibodies recognizing this specific fragment have
been raised, and a sandwich ELISA measuring β-CTX-I
specifically was developed [83-85], as illustrated in
Figure 4E.
Studies of β-CTX-I have shown that it is elevated in
post-menopausal women, and that is has predictive value
for osteoporotic fractures. In addition it has been shown
to respond to various anti-resorptive treatments, and to
have predictive value for treatment efficacy on bone
mineral density (BMD) [11]. Hence the β-CTX-I bio-
marker fits into all the BIPED categories [16]. This
unique triple neo-epitope biomarker is used in both
in vitro, preclinical and clinical studies within the bone
field, as well as in studies of the bone safety of drugs
related to other diseases for example in T2DM trials
using thiazolidinediones (TZDs) [86].
β-cell specific neo-epitopes as novel T2DM biomarkers
Currently the only direct way to assess β-cell mass and β-
cell death in humans is taking biopsies of the pancreas
[6,37], which is invasive and inconvenient to the patient.
The indirect measures of β-cell function, levels of c-peptide
and pro-insulin, are helpful but they cannot describe azymatic cleavage of type I collagen by cathepsin K (Cat K) generates a
agen proteins with lysyl oxidase (LOX) generates a cross-linkede
n generates an isomerized neo-epitope. D) Combined triple
erized conformation. E) Illustration of sandwich ELISA for
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whether before disease diagnosis or during disease pro-
gression. Therefore it is desirable to develop serological
biomarkers reflecting directly the loss of β-cells.
It is suspected that the initiation of β-cell apoptosis,
inflammation and islet remodeling, which are the pro-
cesses responsible for decline in β-cell mass, precede the
loss of function in glycemic control associated with
T2DM [2]. The suggested relationship between β-cell
specific degradation markers and the currently estab-
lished biomarkers like FPG, HbA1c and AGEs, is illu-
strated in Figure 5A. During apoptosis and β-cell loss
different proteases are involved in processing of the cells
and components of the cells. With respect to proteases
involved in processing of β-cell related proteins, pre-
vious studies have implicated matrix metalloproteinase 9
(MMP-9) and MMP-12, cathepsin B, and caspase 3 as
being of high interest [9,14,87-90]. Rationales for their
possible involvement in generation of β-cell biomarkers
are given in Table 2. However, in relation to the pro-
teases it is of importance that neither of these are spe-
cific for β-cells, and have been shown to be involvedFigure 5 Suggested biomarker progression during disease developm
biomarker development during T2DM initiation and progression. 1) Β-cell s
and other early glycation products, 4) Advanced glycation end-products (A
HbA1c. Diagnosed T2DM patients can currently be offered all types of T2D
mass, could direct sub-groups of patients to more specific types of treatmemany different biological functions, unrelated to dia-
betes, and hence cannot on a individual level serve as
biomarkers of β-cell loss. A description of these different
processes is beyond the scope of this paper, and hence
these will not be further discussed here. Hence, what
raises the interest around these proteases is their known
presence and activity in β-cells [9,14,87-90].
It is very likely that one or more β-cell specific proteins
are cleaved by proteases in pathological processes during
disease initiation and progression when β-cells are lost,
and therefore the combination of protease and protein
could result in the generation of a β-cell specific, or at
least selective, biomarker. These cleavages generate neo-
epitopes of proteins some of which are released into
circulation.
Neo-epitopes of β-cell proteins could be of potential
interest for evaluation of β-cell health and death. Some
of the potential protein candidates include: Insulin, IAPP
(amylin), neurexin-1 α, neuroligin-2, gastric inhibitory
polypeptide (GIP) receptor, glucagon-like peptide-1
(GLP-1) receptor, glucose transporter 1 and 2 (GLUT1,
GLUT2), glutamic acid decarboxylase enzyme (GAD65),ent and future segregation of T2DM patients. A) Proposed
pecific degradation markers, 2) Fasting plasma glucose (FPG), 3) HbA1c
GEs). B) Diagnosis of T2DM is based on an elevated concentration of
M treatments. Future segregation of T2DM patients based on β-cell
nts.
Table 2 Proteins and proteases of interest in development of β-cell specific biomarkers
Target protein or Enzyme Rationale
PROTEINS OF INTEREST
Secretory Proteins Insulin • Insulin is highly specific to the β-cells and is produced in high amounts.
• Insulin degradation is a regulated process important for controlling insulin action by removing
and inactivating the hormone.
• Abnormalities in degradation of insulin are present in various pathological conditions including
T2DM, and may be associated with development of clinical symptoms [91].
Amylin (IAPP) • Misfolding and deposit of IAPP is a major pathologic trait in a majority of T2DM patients [4].
• IAPP oligomers have been demonstrated to be toxic to β-cells by inducing apoptosis [6,43-47].
• Depositions of IAPP become a pathological extracellular matrix surrounding the β-cells, and
degradation of this matrix could potentially serve as marker of developing T2DM.
Β-cell Trans-membrane
Proteins
Neuroligin-2,
Neurexin 1α
• Β-cell exocytic machinery is very similar to that of neuronal synapses, and for this reason
the β-cells and neurons have some common traits [92].
• It has been established that β-cells express specific proteins which are also found in the
central nervous system (CNS), such as neuroligin-2 and neurexin-1 α [92].
• As these proteins are rather specific to β-cells and neurons within the CNS, they might be
suitable biomarker candidates for evaluation of β-cell degradation.
GLP-1 receptor,
GIP receptor
• The two incretin receptors GLP-1 receptor (GLP-1R) and GIP receptor (GIPR) are known to be
expressed in pancreatic β-cells, but not exclusively by this cell type.
• Activation of both GLP-1R and GIPR is known to stimulate insulin synthesis and insulin release
[93,94], and both receptors have therefore been suggested as potential targets for the
treatment of diabetes.
• GLP-1R and GIPR have been demonstrated to form heterodimers, which could be of importance
for fine-tuning incretin response [95].
• Hyperglycemia has been found to lower the expression of both GLP-1R and GIPR, contributing
to the diminished incretin action in hyperglycaemic states and diabetes [96,97].
GLUT1, GLUT2 • Glucose transporters, GLUT1 and GLUT2, are important for the functionality of β-cells.
• GLUT1 and GLUT2 are expressed in several tissues. However, neo-epitopes, which are specific
to the pathological events involved with loss of β-cells, could be potential β-cell markers.
T1DM Autoimmune
Targets
GAD 65, IA-2, ZnT8 • GAD65, IA-2 and ZnT8 are all established autoantigens in T1DM [98-100].
• Autoantibodies directed against these autoantigens have also been identified in some T2DM
patients [101].
• It has been found that GAD65 is released during β-cell injury, and circulating GAD65 would
therefore be a suitable marker for β-cell ill-health [2,102].
• It has been established that measurements of GAD65 are able to detect β-cell death at a time
point preceding the onset of hyperglycemia [2,102].
PROTEASES OF INTEREST
Caspase 3 • Caspase 3 is a key enzyme in the enzymatic cascade initiating cell apoptosis.
• Several pathological processes lead to β-cell apoptosis [4], rendering caspase 3 an interesting
effector protease.
MMP-12 • MMP-12 is expressed primarily by macrophages and monocytes.
• Β-cell loss can occur as consequence of local inflammation, and therefore, MMP-12 could be a
protease of interest.
MMP-9 • MMP-9 is expressed primarily by macrophages and T-cells
• Β-cell loss can occur as consequence of local inflammation, and therefore, MMP-9 could be a
protease of interest.
Cathepsin B • Cathepsin B is known to be present in pancreatic juice.
• Cathepsin B has been speculated to be involved in the pathology of pancreatitis [103,104], and
it could be hypothesized that similar mechanisms might, to some extent, be involved in
development of T2DM.
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(ZnT8). In Table 2, this partial list of protein candidates
is given, with rationales for the suitability of the chosen
proteins as β-cell biomarkers.To obtain an early diagnosis of diabetes we propose
that β-cell loss can be detected by proteins derived di-
rectly from β-cells, preferably extracellular. A general
issue for most of the suggested novel biomarkers is the
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amylin as exceptions. All of the mentioned proteins are
highly expressed in β-cells, but also in other, often larger
tissues. This could potentially mask any β-cell specific
signal in the background noise coming from competing
tissues. However the specificity could be obtained by the
combination of high levels of expression in the pancreas
together with a specific pattern of cleavage only
observed from the pancreas. Proteins highly expressed
in β-cells are likely to be cleaved and excreted into the
bloodstream and the tissue- and disease specific protein
fingerprinting approach described in the previous sec-
tion could be applied, but it remains to be elucidated.
Amylin is co-secreted with insulin and is another hall-
mark secretory peptide hormone specific to pancreatic
β-cells [105]. The emergence of IAPP plaques and the
association with β-cell apoptosis [6,44] and β-cell specifi-
city makes amylin a prime candidate for protein finger
printing. However, amylin is readily degraded by insulin
degrading enzyme (IDE) found highly expressed in kidney
and muscle [106], which could make protease generated
amylin fragments somewhat short lived.
Incretin hormones like GLP-1 and GIP have the ability
to enhance insulin secretion and thereby improving
clearance rate of glucose from the blood [93,94]. The
direct effect is mediated by receptors expressed highly
by the pancreatic β-cells. The receptors are also found in
other tissues indicating an indirect effect e.g. from the
nervous tissue [94]. Furthermore GLP-1 has shown anti-
apoptotic effects and induction of neo-genesis in β-cells
and insulin biosynthesis [94]. As the incretin receptors
are expressed in β-cells these too are likely to be
degraded upon β-cell disruption.
A similar fate could be attributed to other trans-
membrane proteins such as GLUT1 and GLUT2, which
are highly expressed in human and rodent pancreatic β-
cells, respectively [107].
Neurons and β-cells have many similarities especially
in the exocytotic machinery which in neurons is respon-
sible for release of neurotransmitters and in β-cells me-
diate the release of insulin granules [108]. Proteins
responsible for docking of vesicles and scaffolding pro-
teins responsible for keeping the synapse tight is found
both in neurons and β-cells [92]. Neurexin-1α and
neuroligin-2 was identified in a systematic study of
human tissue mRNAs designed to identify highly
expressed, membrane-associated, human islet-specific
proteins [109], and both proteins are involved in secre-
tion of both neurotransmitters and insulin [110,111].
Neuroligin-2 and neurexin-1α are involved in vesicular
docking and organizing the vesicles in the pre-synaptic
area [110,111].
Another class of proteins of interest in relation to
novel biomarkers are the targets of type I diabetesautoimmune antibodies and suggested potential biomar-
kers include glutamic acid decarboxylase enzyme
(GAD65), islet cell antigen 512 (IA-2) and zinc trans-
porter 8 (ZnT8) [2,98-100,102]. The specific destruction
of pancreatic β-cells suggests high cell specificity even if
the target proteins are expressed in other tissues as well.
The proteins are ready available to the immune system and
the surrounding tissues and could be potential targets for
proteases released during ECM remodeling/destruction or
by infiltrating macrophages. The autoimmune targets are
either specific for β-cells or off-targets are otherwise pro-
tected (e.g. blood brain barrier).
To summarize, detection of any β-cell generated neo-
epitopes in serum or plasma could prove valuable as
biomarkers reflecting β-cell health and death aid our
understanding of β-cell pathology in the initiation and
progression of T2DM.Conclusions
It is not fully understood how β-cells, which play a critical
role in both T1DM and T2DM, change during disease ini-
tiation and progression, and during drug interventions.
This is primarily due to shortcomings in evaluation
techniques.
We here suggest developing novel neo-epitope bio-
markers, measurable in serum or plasma that will reflect
β-loss and be used alongside existing markers for dia-
betes evaluation. Such novel biomarkers may segregate
T2DM patients into appropriate treatment groups, based
on the β-cell status of the individual patient, as illu-
strated in Figure 5B. Drug development in T2DM would
also benefit from β-cell specific serological markers, as
evaluation of β-cell health is suspected to become an im-
portant parameter, in future clinical trials.
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